Physicians who care for critically ill people with opioid use disorder frequently face medical, legal, and ethical questions related to the provision of life-saving medical care. We examine a complex medical case that illustrates these challenges in a person with relapsing injection drug use. We focus on a specific question: Is futility an appropriate and useful standard by which to determine provision of life-saving care to such individuals? If so, how should such determinations be made? If not, what alternative decisionmaking framework exists? We determine that although futility has been historically utilized as a justification for withholding care in certain settings, it is not a useful standard to apply in cases involving people who use injection drugs for non-medical purposes. Instead, we are welladvised to explore each patient's situation in a holistic approach that includes the patient, family members, and care providers in the decision-making process. The scope of the problem illustrated demonstrates the urgent need to definitively improve outcomes in people who use injection drugs. Increasing access to high quality medication-assisted treatment and psychiatric care for individuals with opioid use disorder will help our patients achieve a sustained remission and allow us to reach this goal.
Get full access to this article
View all access options for this article.
References
1.
“National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C,”Hepatology26 (September1997): 2S–10S, available at <https://doi.org/10.1002/hep.510260701> (last visited April 6, 2018).
2.
B. R.Edlinet al., “Is it Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?,”New England Journal of Medicine345 (July19, 2001): 211–214, available at <https://doi.org/10.1056/NEJM200107193450311> (last visited April 6, 2018).
3.
American Association for the Study of Liver Diseases, “When and in Whom to Initiate HCV Therapy | HCV Guidance,”available at <https://www.hcvguidelines.org/evaluate/when-whom> (last visited April 6, 2018).
4.
P.Martinet al., “Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation,”Hepatology59 (2014): 1144–1165.
5.
S. C.Hull and F.Jadbabaie, “When Is Enough Enough? The Dilemma of Valve Replacement in a Recidivist Intravenous Drug User,”The Annals of Thoracic Surgery97, no. 5 (May2014): 1486–1487, available at <https://doi.org/10.1016/j.athoracsur.2014.02.010> (last visited April 6, 2018).
6.
J. P.Hoffmann, “The Historical Shift in the Perception of Opiates: From Medicine to Social Menace,”Journal of Psychoactive Drugs22 (1990): 53–62.
7.
J. C.Ballantyne and J.Mao, “Opioid Therapy for Chronic Pain,”New England Journal of Medicine349 (November13, 2003): 1943–1953, available at <https://doi.org/10.1056/NEJMra025411> (last visited April 6, 2018).
8.
N.Heather, “Q: Is Addiction a Brain Disease or a Moral Failing? A: Neither,”Neuroethics10, no. 1 (April1, 2017): 115–124, available at <https://doi.org/10.1007/s12152-016-9289-0> (last visited April 6, 2018).
9.
N. D.Volkow, G. F.Koob, and A. T.McLellan, “Neurobiologic Advances from the Brain Disease Model of Addiction,”New England Journal of Medicine374 (2016): 363–371.
10.
L. M.Baddouret al., “Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications,”Circulation132 (2015): 1435–1486.
11.
R. S.Garfeinet al., “Viral Infections in Short-Term Injection Drug Users: The Prevalence of the Hepatitis C, Hepatitis B, Human Immunodeficiency, and Human T-Lymphotropic Viruses,”American Journal of Public Health86 (1996): 655–661.
12.
R. H.Westbrook and G.Dusheiko, “Natural History of Hepatitis C,”Journal of Hepatology61 (2014): S58–68.
13.
R. P.Matticket al., “Methadone Maintenance Therapy versus No Opioid Replacement Therapy for Opioid Dependence,”The Cochrane Library (2009).
14.
J.Kakkoet al., “1-Year Retention and Social Function after Buprenorphine-Assisted Relapse Prevention Treatment for Heroin Dependence in Sweden: A Randomised, Placebo-Controlled Trial,”The Lancet361 (2003): 662–668; J. M. Soeffing et al., “Buprenorphine Maintenance Treatment in a Primary Care Setting: Outcomes at 1 Year,” Journal of Substance Abuse Treatment 37 (2009): 426–430; D. A. Fiellin et al., “Counseling Plus Buprenorphine–naloxone Maintenance Therapy for Opioid Dependence,” New England Journal of Medicine 355 (2006): 365–374.
15.
J.Mathewet al., “Clinical Features, Site of Involvement, Bacteriologic Findings, and Outcome of Infective Endocarditis in Intravenous Drug Users,”Archives of Internal Medicine155, no. 15 (1995): 1641-1648.
16.
G.Hubbellet al., “Presentation, Management, and Follow-up Evaluation of Infective Endocarditis in Drug Addicts,”American Heart Journal102, no. 1 (1981): 85-94.
17.
O. B.Østerdalet al., “Cardiac Surgery for Infective Endocarditis in Patients with Intravenous Drug Use,”Interactive Cardiovascular and Thoracic Surgery22, no. 5 (2016): 633-640.
18.
C.Rivoisyet al., “Prosthetic Valve Candida Spp. Endocarditis: New Insights into Long Term Prognosis - the ESCAPE Study,”Clinical Infectious Diseases66, no. 6 (2017): cix913-cix913, available at <https://doi.org/10.1093/cid/cix913> (last visited April 6, 2018).
19.
D. J. C.Wilkinson and J.Savulescu, “Knowing When to Stop: Futility in the Intensive Care Unit,”Current Opinion in Anaesthesiology24 (2011): 160.
20.
J.La Puma, C. K.Cassel, and H.Humphrey, “Ethics, Economics, and Endocarditis: The Physician’s Role in Resource Allocation,”Archives of Internal Medicine148, no. 8 (August1988): 1809–1811, available at <https://doi.org/10.1001/archinte.1988.00380080087023> (last visited April 6, 2018).
21.
See Hull, supra note 5.
22.
L. S.Ganseraet al., “High-Risk Cardiac Surgery in Patients with Intravenous Drug Abuse and/or Active Hepatitis C or HIV Infection: An Ethical Discussion of Six Cases,”The Thoracic and Cardiovascular Surgeon64, no. 1 (January2016): 2–5, available at <https://doi.org/10.1055/s-0035-1551682> (last visited April 6, 2018).
23.
J. N.Kirkpatrick and J. W.Smith, “Dilemmas in Dual Disease: Complexity and Futility in Prosthetic Valve Endocarditis and Substance Use Disorder,”The American Journal of Bioethics18, no. 1 (January2, 2018): 76–78, available at <https://doi.org/10.1080/15265161.2017.1401160> (last visited April 6, 2018).
24.
T. M.Pope, “Medical Futility Statutes: No Safe Harbor to Unilaterally Refuse Life-Sustaining Treatment,”Tennessee Law Review75 (2007): 1.
25.
National Conference of Commissioners on Uniform State Laws, “Uniform Health-Care Decisions Act,”Issues in Law & Medicine22, no. 1 (2006).
26.
T. M.Pope, “Dispute Resolution Mechanisms for Intractable Medical Futility Disputes,”New York Law School Law Review58 (2013): 347.
R. A.Nishimuraet al., “2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,”Circulation129, no. 23 (June10, 2014): e521–643, available at <https://doi.org/10.1161/CIR.0000000000000031> (last visited April 6, 2018).
30.
See Pope, No Safe Harbor, supra note 24 at 117.
31.
See Pope, No Safe Harbor, supra note 24.
32.
Marsala v. Yale-New Haven Hosp., Inc., 166 Conn.App. 432.
33.
T. M.Pope, “Involuntary Passive Euthanasia in US Courts: Reassessing the Judicial Treatment of Medical Futility Cases,”Marquette Elder’s Advisor9, no. 2 (2007): 229-268.
J. O.Merrillet al., “Mutual Mistrust in the Medical Care of Drug Users,”Journal of General Internal Medicine17 (2002): 327–333.
37.
D.Z.Buchman and M.-J.Lynch, “An Ethical Bone to PICC: Considering a Harm Reduction Approach for a Second Valve Replacement for a Person Who Uses Drugs,”American Journal of Bioethics18, no. 1 (2018): 79-81.
38.
N. K.Shresthaet al., “Injection Drug Use and Outcomes After Surgical Intervention for Infective Endocarditis,”The Annals of Thoracic Surgery100, no. 3 (September1, 2015): 875–882, available at <https://doi.org/10.1016/j.athoracsur.2015.03.019> (last visited April 6, 2018).
M.Ruchika, “Does Blame Trump Benefit in Treatment Decisions? Nonadherence and Cardiac Surgery,”The American Journal of Bioethics18, no. 1 (January2, 2018): 81–83, available at <https://doi.org/10.1080/15265161.2017.1401158> (last visited April 6, 2018).
